CREMA TRATTAMENTO PSORIASI OFFERTA -50% !

Home Uncategorized Psorilax:Per i bambini |crema urea per psoriasi

Psorilax:Per i bambini |crema urea per psoriasi

0
Psorilax:Per i bambini |crema urea per psoriasi

CREMA TRATTAMENTO PSORIASI OFFERTA -50% !

Psorilax: prezzo, funziona, recensioni, opinioni, ingredienti

“When treating moderate to severe acne, I like to prescribe a tazarotene treatment due to the retinoid’s efficacy, but find patients often struggle with tolerability issues, such as dry, irritated skin,” said Emil A. Tanghetti , M.D., lead ARAZLO study investigator and founder, Center for Dermatology and Laser Surgery, Sacramento, Calif. “This newly published data sheds light on the utility of ARAZLO, a new treatment option that features the efficacy of tazarotene along with improved tolerability in a lotion vehicle, which is easily spreadable and aesthetically pleasing. I look forward to offering this treatment to my patients with acne in the coming months.”

“These data, combined with our recent FDA approval of ARAZLO, demonstrate our continued commitment to bringing treatment innovations to market that meet the ever-evolving needs of dermatologists and their patients who struggle with acne,” said Bill Humphries , president, Ortho Dermatologics. “We look forward to launching the product later this year, providing dermatologists with a lower concentration of tazarotene lotion that helps effectively clear moderate to severe acne.”

Story continues

Patients were randomized to receive ARAZLO or placebo lotion, and all patients who were provided the study drug were included in the intent-to-treat (ITT) population. The co-primary endpoints were EGSS and absolute reduction in inflammatory and non-inflammatory lesion counts. Patients who had at least a two-grade reduction from baseline EGSS at week 12, and an EGSS of ‘clear’ or ‘almost clear’ were considered a treatment success. Secondary endpoints included percent change in both lesion counts from baseline at each study visit and absolute change in Acne-Specific Quality of Life questionnaire (Acne-QoL) domain scores. Safety, adverse events (AEs) and cutaneous tolerability were evaluated throughout the study.

  • ARAZLO may cause birth defects if used during pregnancy.
  • You must not be pregnant when you start using ARAZLO or become pregnant during treatment.
  • Use effective birth control during treatment.
  • Stop using ARAZLO and tell your healthcare provider right away if you become pregnant during treatment.
  • have eczema or any other skin problems.
  • are breastfeeding or plan to breastfeed. If you use ARAZLO while breastfeeding, use it for the shortest time needed. Do not apply ARAZLO directly to the nipple and surrounding area to avoid exposing your child to the medicine.
  • You should avoid sunlamps, tanning beds, and ultraviolet light during treatment with ARAZLO.
  • Minimize exposure to sunlight; you could get severe sunburn.
  • Avoid using ARAZLO on skin with eczema or sunburned skin because it may cause severe irritation.
  • These are not all the possible side effects of ARAZLO. Call your doctor for medical advice about side effects. You may report side effects to Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088.

    here for full Prescribing Information, including Patient Information.” data-reactid=”54″>Please click here for full Prescribing Information, including Patient Information.

    www.ortho-dermatologics.com.” data-reactid=”55″>About Ortho Dermatologics
    Ortho Dermatologics is one of the largest prescription dermatology and aesthetics businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Ortho Dermatologics portfolio includes several leading acne, anti-fungal and corticosteroid-responsive dermatoses products. More information can be found at www.ortho-dermatologics.com.

    www.bauschhealth.com.” data-reactid=”56″>About Bausch Health
    Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

  • Tanghetti EA, et al. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials. J Drugs Dermatol. 2020;19(1): doi:10.36849/JDD.2020.3977.
  • Cook-Bolden F, et al. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males. J Drugs Dermatol. 2020;19(1): doi:10.36849/JDD.2020.3979.
  • American Academy of Dermatology. (2019). Skin conditions by the numbers. Retrieved from https://www.aad.org/media/stats/conditions/skin-conditions-by-the-numbers. Accessed Jan. 6, 2020 .
  • Mayo Clinic. (2018). Acne. Retrieved from https://www.mayoclinic.org/diseases-conditions/acne/symptoms-causes/syc-20368047. Accessed Jan. 6, 2020 .
  • Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

    http://www.prnewswire.com/news-releases/ortho-dermatologics-announces-publication-of-pivotal-phase-3-data-on-arazlo-tazarotene-lotion-0-045-in-the-journal-of-drugs-in-dermatology-jdd-300985477.html” data-reactid=”116″>View original content to download multimedia:http://www.prnewswire.com/news-releases/ortho-dermatologics-announces-publication-of-pivotal-phase-3-data-on-arazlo-tazarotene-lotion-0-045-in-the-journal-of-drugs-in-dermatology-jdd-300985477.html

    SOURCE Bausch Health Companies Inc.

    http://www.newswire.ca/en/releases/archive/January2020/13/c4192.html” data-reactid=”135″>View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2020/13/c4192.html

    CREMA TRATTAMENTO PSORIASI OFFERTA -50% !